Morpholinos, morpholino upregulating, and associated methods

Abstract

Various methods and compositions relating to vascular endothelial growth factor receptor 2 (VEGFR2) are provided. In one aspect, a method of increasing expression of the soluble form of VEGFR2 (sVEGFR2) in a subject can include binding an antisense morpholino to an exon13-intron13 splicing site of VEGFR2 mRNA such that the VEGFR2 mRNA is spliced into a sVEGFR2 isoform.

1 . A method of increasing expression of sVEGFR2 in a subject, comprising:
 binding an antisense morpholino to an exon13-intron13 splicing site of VEGFR2 mRNA such that the VEGFR2 mRNA is spliced into an sVEGFR2 isoform.   
     
     
         2 . The method of  claim 1 , wherein the morpholino binds to the splicing site with a homology of at least about 75%. 
     
     
         3 . The method of  claim 1 , wherein the morpholino binds to the splicing site with a homology of at least about 95%. 
     
     
         4 . The method of  claim 1 , wherein the morpholino is at least about 75% homologous to SEQ ID 001. 
     
     
         5 . The method of  claim 1 , wherein the morpholino is at least about 95% homologous to SEQ ID 001. 
     
     
         6 . The method of  claim 1 , wherein the morpholino has a sequence of SEQ ID 001. 
     
     
         7 . A method of inhibiting neovascularization in a subject, comprising:
 binding an antisense morpholino to an exon13-intron13 splicing site of VEGFR2 mRNA such that the VEGFR2 mRNA is spliced into an sVEGFR2 isoform.   
     
     
         8 . The method of  claim 7 , wherein the morpholino binds to the splicing site with a homology of at least about 75%. 
     
     
         9 . The method of  claim 7 , wherein the morpholino binds to the splicing site with a homology of at least about 95%. 
     
     
         10 . The method of  claim 7 , wherein the morpholino is at least about 75% homologous to SEQ ID 001. 
     
     
         11 . The method of  claim 7 , wherein the morpholino is at least about 95% homologous to SEQ ID 001. 
     
     
         12 . The method of  claim 7 , wherein the morpholino has a sequence of SEQ ID 001. 
     
     
         13 . A pharmaceutical composition for increasing expression of sVEGFR2 in a subject, comprising:
 a pharmaceutically effective carrier including a morpholino capable of binding to an exon13-intron13 splicing site of VEGFR2 mRNA to facilitate increased expression of sVEGFR2.   
     
     
         14 . The composition of  claim 13 , wherein the morpholino sequence is at least about 75% homologous to the splicing site sequence. 
     
     
         15 . The composition of  claim 13 , wherein the morpholino sequence is at least about 95% homologous to the splicing site sequence. 
     
     
         16 . The composition of  claim 13 , wherein the morpholino includes an oligomer selected from the group consisting of SEQ ID 001 to SEQ ID 043. 
     
     
         17 . The composition of  claim 13 , wherein the morpholino has a sequence of SEQ ID 001.